• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Exagen Inc.

    5/8/25 4:06:09 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    8-K
    false 0001274737 0001274737 2025-05-07 2025-05-07
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 7, 2025

     

     

    EXAGEN INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39049   20-0434866

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    1261 Liberty Way

    Vista, CA 92081

    (Address of principal executive offices) (Zip Code)

    (760) 560-1501

    (Registrant’s telephone number, including area code)

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share   XGN   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    On May 8, 2025, Exagen Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) by and between Canaccord Genuity LLC (the “Underwriter”) relating to the issuance and sale of an aggregate of 3,350,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to the Underwriter at a price to the public of $5.25 per share (the “Offering”). Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriter a 30-day option to purchase up to an additional 502,500 shares of Common Stock in the Offering (the “Option Shares” and together with the Firm Shares, the “Shares”). The Offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions. All of the Shares in the Offering are being sold by the Company.

    The net proceeds to the Company from the Offering are expected to be approximately $16.2 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes. The Company may also use a portion of the net proceeds from the Offering to acquire, in-license or invest in products, technologies or businesses that complement the Company’s business. However, the Company does not have binding agreements or commitments for any acquisitions or investments outside the ordinary course of business at this time.

    The Shares are being offered and sold pursuant to a prospectus supplement, dated May 8, 2025 (the “Prospectus Supplement”), to be filed with the Securities and Exchange Commission (“SEC”) on May 8, 2025, and an accompanying base prospectus that forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-275632), which was previously filed with the SEC on November 17, 2023 and declared effective on November 29, 2023.

    The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement that is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, delivered an opinion as to legality of the issuance and sale of the Shares in the Offering, a copy of which is filed as Exhibit 5.1 to this Current Report on Form 8-K and incorporated herein by reference.

    Forward-Looking Statements

    This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of proceeds expected from the Offering, and the timing and certainty of completion of the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the Company’s ability to complete the Offering on favorable terms, or at all, as well as other risks detailed from time to time in the Company’s filings with the SEC, including in its Annual Report on Form 10-K for the year ended December 31, 2024 and the Prospectus Supplement. These documents contain important factors that could cause actual results to differ from current expectations and from the forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.

     

    Item 8.01

    Other Events.

    On May 7, 2025, the Company issued a press release announcing the launch of the Offering, and on May 8, 2025, the Company issued a press release announcing the pricing of the Offering. Copies of the press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

    The following exhibits are being filed herewith:

     

    Exhibit

     No. 

      

    Document

     1.1    Underwriting Agreement, dated May 8, 2025, by and between Exagen Inc. and Canaccord Genuity LLC.
     5.1    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
    99.1    Press Release dated May 7, 2025.
    99.2    Press Release dated May 8, 2025.
    23.1    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        EXAGEN INC.
    Date: May 8, 2025     By:  

    /s/ Jeffrey G. Black

          Jeffrey G. Black
          Chief Financial Officer
    Get the next $XGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    7/23/2025$12.00Buy
    Craig Hallum
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    SEC Filings

    See more
    • Exagen Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - EXAGEN INC. (0001274737) (Filer)

      7/17/25 4:33:47 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Exagen Inc.

      EFFECT - EXAGEN INC. (0001274737) (Filer)

      7/3/25 12:15:14 AM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form S-3 filed by Exagen Inc.

      S-3 - EXAGEN INC. (0001274737) (Filer)

      6/20/25 4:21:58 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exagen Inc. Appoints Chas McKhann to Board of Directors

      CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

      7/17/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

      CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exa

      7/15/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

      CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

      6/23/25 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Exagen with a new price target

      Craig Hallum initiated coverage of Exagen with a rating of Buy and set a new price target of $12.00

      7/23/25 7:55:19 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight

      8/5/22 9:00:50 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Keybanc reiterated coverage on Exagen with a new price target

      Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously

      11/11/21 4:33:21 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Kim Paul

      4/A - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 8:32:07 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Stokes Frank

      4 - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 6:49:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Kim Paul

      4 - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 5:57:17 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/19/24 7:24:38 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/18/24 6:32:33 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      5/16/24 8:02:50 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exagen Inc.

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      12/12/24 5:00:54 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 2:42:55 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 7:12:55 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Financials

    Live finance-specific insights

    See more
    • Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

      CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exa

      7/15/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

      CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194  $27,267 Trailing-twelve-month average selling price (ASP) $419  $377           Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million

      5/5/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

      4/21/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Exagen Inc. Appoints Chas McKhann to Board of Directors

      CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Board member, President and CEO of Silk Road Medical, and prior to that, Apollo Endosurgery, both Nasdaq-listed companies acquired by Boston Scientific, resulting in significant shareholde

      7/17/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

      CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

      6/23/25 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

      CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

      8/1/24 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care